(Q58034401)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Sequential therapy with adefovir dipivoxil and pegylated interferon alfa-2a for HBeAg-negative patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

R Moucari

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

N Boyer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M-P Ripault

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

C Castelnau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

V Mackiewicz

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Dauvergne

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Vidaud

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M-H N Chanoine

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

P Marcellin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

17 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

580-586

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

2 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Therapy of hepatitis B -- viral suppression or eradication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Chronic hepatitis B: back to the future with HBsAg

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01332.X

10.1111/J.1365-2893.2010.01332.X

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20487260%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference